CytoMed Therapeutics Limited

$1.02 USD

$0 (0.0%)

Volume: 2.64K
Average Volume: 19.16K
Market Capitalization: $12.07M
P/E Ratio: -3.25
Dividend Yield: 0.00%
Price Target

Year High: $3.68
Year Low: $0.68
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $5.17

Industry, Sector & symbol

Stock Exchange	NASDAQ
CEO	Chee Kong Choo
Industry	Biotechnology
Sector	Healthcare
Current Symbol	GDTC
CUSIP	None
CIK	0001873093
Web	https://w2.cytomed.sg
Phone	65 6250 7738
Currency	USD
Employees	42
Country	SG

Liquidity

Debt-to-Equity Ratio	0.07
Payout Ratio	0.00
Current Ratio	5.17
Quick Ratio	3.66
Cash Ratio	2.95

Sales & Book Value

Annual Sales	$319.2K
Price / Sales	24.23
Cash Flow	-0.54
Price / Cash Flow	-2.46
Price / Book	2.37

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecast Upside/Downside	%
Consensus Rating	Strong Sell
Rating Score(0-5)	1
Research Coverage	1 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$0.33
Trailing P/E Ratio	-3.25
PEG Ratio	0.20
P/E Growth	0.20
Net Income	-$3.92M
Net Margin	-754.66%
Pretax Margin	-758.20%
Return on Equity	-70.74%
Return on Assets	-60.74%

Financials Score

AltmanZ Score	3.22
Piotroski Score	2.00
Working Capital	2.95M
Total Assets	7.98M
Ebit	-5.69M
Market Cap	15.74M
Total Liabilities	1.13M

Poll Results

About CytoMed Therapeutics Limited (NASDAQ:GDTC) Stock

CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunother ... apy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.

Frequently Asked Questions

What is the current CytoMed Therapeutics Limited (GDTC) stock price?: CytoMed Therapeutics Limited(NASDAQ:GDTC) stock price is $1.02 in the last trading session. During the trading session, GDTC stock reached the peak price of $3.68 while $0.68 was the lowest point it dropped to. The percentage change in GDTC stock occurred in the recent session was 0.0% while the dollar amount for the price change in GDTC stock was $0.
GDTC's industry and sector of operation?: The NASDAQ listed GDTC is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of GDTC?: Jieming Zeng | Chief Scientific & Medical Officer and Director
Chee Kong Choo | Executive Chairman
Yoong Ying Tan | Chief Corporation Officer
Yvonne Goh | Chief Financial Officer
Tien Wee Luk | Chief Clinical Officer
How many employees does GDTC have?: Number of GDTC employees currently stands at 42. GDTC operates from 1 Commonwealth Lane, No. 08-22, Singapore, CE 149544, SG.

Link for GDTC official website?: Official Website of GDTC is: https://w2.cytomed.sg
How do I contact GDTC?: GDTC could be contacted at phone #65 6250 7738 and can also be accessed through its website. GDTC operates from 1 Commonwealth Lane, No. 08-22, Singapore, CE 149544, SG.
How many shares of GDTC are traded daily?: The average number of GDTC shares traded daily for last 3 months was 19.16K.
What is the market cap of GDTC currently?: The market value of GDTC currently stands at $12.07M with its latest stock price at $1.02